




# IMPACT REPORT 2022

CRIS CANCER FOUNDATION



# MESSAGE FROM THE CHAIR



- 1. MESSAGE FROM THE CHAIR** P.03
- 2. ABOUT CRIS CANCER** P.05
- 3. FUNDING IN THE WORLD** P.08
- 4. IMPACT ON RESEARCH** P.11
- 5. CANCER RESEARCH PROJECTS** P.13
- 6. MULTIDISCIPLINARY UNITS** P.14
- 7. SUPPORTING RESEARCHERS** P.15
- 8. OUR FIGURES** P.17
- 9. HIGHLIGHTS 2022** P.18



**LOLA MANTEROLA**  
PRESIDENT

*Research is what gave - and continues to give - us hope.*

Dear CRIS supporters,

Welcome to our Impact Report.

Here you'll find a summary of the CRIS Cancer Foundation's work in supporting lifesaving cancer research worldwide.

Cancer research lies at the heart of improving and saving patients' lives. Our goal is to accelerate that research so that new treatments can be made available quickly to patients who don't respond to conventional treatments.

Your support is crucial in helping us to empower the talented researchers, institutes and public hospitals that make our goal a reality.

Cancer patients don't have time to waste!

We would like to offer you our most heart felt gratitude for your continued support. We very much hope you enjoy reading about the impact you have made on so many cancer patients' lives.

Once again, thank you.

LOLA MANTEROLA  
CRIS CANCER PRESIDENT

**CRIS Cancer Foundation is an independent non-profit organisation, fully dedicated to facilitating and developing research to beat cancer as a serious health issue.**

## ABOUT CRIS CANCER

We are an **international charity** that funds research into pioneering new cancer treatments to give the best chance of survival to patients who do not respond to conventional treatments.

By stepping in where there are gaps in **funding, and collaborating and building alliances worldwide with top research institutions**, we support research scientists to speed up innovative therapies – bringing hope to thousands of cancer patients.

In addition, since its creation in 2011, the CRIS Cancer Foundation has been **identifying talent amongst researchers** worldwide. Through our **grants and fellowships**, we give scientists the funding and **support** they need throughout their research **careers** to make significant discoveries in cancer treatments.

Our cancer **facilities in public hospitals (Units)** and research centres in Europe are giving more patients the chance to access new treatments. Teams of doctors, researchers, bioinformatics, nurses, clinical trial technicians and immunologists work together in CRIS units to treat every type of cancer.



**INTERNATIONAL CHARITY**



**FUNDING, COLLABORATING AND BUILDING ALLIANCES**



**RECOGNISING THE SCIENTIFIC TALENT AND SUPPORTING CAREERS**



**LONG TERM COMMITMENT STRATEGY ALLOWS CLOSER RELATIONSHIP WITH RESEARCHERS**



**FACILITIES IN PUBLIC HOSPITALS**



**GIVING PATIENTS THE CHANCE TO ACCESS NEW TREATMENTS.**

We all make it possible



# WE ARE CRIS

## WE ARE GLOBAL



**SPAIN**  
TRUSTEE BOARD

**UK**  
TRUSTEE BOARD

**FRANCE**  
TRUSTEE BOARD

**Lola Manterola**  
Gonzalo Rodriguez  
Eduardo Giménez  
Daniel Guerrero  
David Lafuente  
Cristina Lasvignes  
Joaquin Martínez  
Natalia Martínez  
Diego Megía  
Francisco Miret  
Paulino Moraleda  
Ana Zunzarren

**Lola Manterola**  
Diego Megía  
Nicola Amoroso  
Marta Brime  
Eleonor Creaturo  
Fernando Delgado  
Fefi Díaz  
Nuria Martí  
Alvaro Portanet  
Snigdha Singh

**Raoul Salomon**  
Diego Megía  
Lola Manterola  
Melvina Mossié  
Anne-Sophie Rio  
Stephane Rio

### INTERNATIONAL SCIENTIFIC COMMITTEE

**Prof. Paul Workman**  
Institute of Cancer Research (ICR)  
London (UK)

**Prof. Rajesh Chopra**  
Apple Tree Partners (ATP)  
London (UK)

**Dr. Kevin Harrington**  
Institute of Cancer Research (ICR)  
London (UK)

**Dr. Joaquín Martínez**  
H120-CNIO-UCM  
Madrid (Spain)

**Dr. Paul S. Mischel**  
Stanford University  
California (US)


**Dr. Amanda Psyrris**  
Attikon University Hospital National  
Kapodistrian University of Athens (NKUA)  
Athens (Greece)

**Dra. Lillian Siu**  
Princess Margaret Cancer Centre  
Toronto (Canada)

**Dr. Fabrice André**  
Gustave Roussy  
Paris (France)

TEAMS | RESEARCHERS | AMBASSADORS | VOLUNTEERS

The CRIS community is made up of a network of people following the same dream: to fight cancer through research. Together we are beating cancer. Together we are stronger



# CRIS FUNDING AROUND THE WORLD



The CRIS commitment to cancer research is global. We have built an extensive network of international cooperative alliances with **cutting-edge research centres and researchers** to combat cancer.

**65**   
**RESEARCH CENTRES AROUND THE WORLD**

## CRIS Projects

- **London:** Institute of Cancer Research (ICR), Great Ormond Street Hospital (GOSH)
- **Paris:** Institute Gustave Roussy
- **Nize:** Centre Méditerranéen de médecine moléculaire
- **Massachusetts:** General Hospital Cancer Center, US
- **Madrid:** Hospital 12 de Octubre, CNIO, Hospital de la Princesa, Hospital Clínico San Carlos, MD Anderson, Hospital Universitario de la Paz, Hospital Universitario Niño Jesús, Centro Nacional de Biología Molecular Severo Ochoa, Centro Integral Oncológico Clara Campal.
- **Barcelona:** IRB, Hospital Sant Joan de Deu, VHIO, Hospital Clínic, MIM
- **Pamplona:** Clínica Universidad de Navarra
- **Bilbao:** CIC bioGUNE
- **Vitoria:** Universidad del País Vasco
- **Málaga:** IBIMA
- **Sevilla:** IBIS Sevilla
- **Valencia:** INCLIVA Valencia
- **Salamanca:** CIC
- **Albacete:** CHUA
- **Murcia:** Instituto de Neurociencias CSIC-UMH
- **Santiago de Compostela:** IDIS

## Co-Funding with International Institutions

- **London:** University College (PCF)
- **Newcastle:** Newcastle University (PCF)
- **Oxford:** Oxford University (PCF)
- **Munich:** Technical University (PCF)
- **Barcelona:** VHIR, Spain (FKC)
- **Utrecht:** Princess Maxima Center (FKC)
- **Paris:** Institute Gustave Roussy (FKC)
- **Amsterdam:** University of Amsterdam (FKC)
- **Israel:** Schneider Children's Medical Center (FKC)
- **Dublin:** University College Dublin (FKC)
- **Cambridge:** University of Cambridge, The Gurdon Institute (Damon Runyon)
- **Tübingen:** Eberhard Karl University (Damon Runyon)
- **Israel:** Weizmann Institute of Science (Damon Runyon)
- **Geneva:** University of Geneva (Damon Runyon)

PCF: Prostate Cancer Foundation (US)  
 FKC: Fight Kids Cancer (Europe)

## CRIS Research Fellowships

- **London:** ICR, Royal Marsden NHS Foundation Trust
- **Oxford:** Oxford University
- **Southampton:** University Hospital
- **Glasgow:** The Beatson Cancer Center
- **Barcelona:** VHIR, VHIO
- **Madrid:** Universidad Complutense de Madrid, Universidad Francisco de Vitoria
- **Murcia:** Hospital Virgen de la Arrixaca
- **Paris:** Institute Gustave Roussy
- **Lyon:** Centre Hospitalier
- **Aarhus:** Aarhus University Hospital
- **Utrecht:** Princess Maxima Center
- **Boston:** Dana-Farber Cancer Institute
- **Nashville:** Vanderbilt Ingram Cancer Center
- **New York:** Mount Sinai School of Medicine, Weill Cornell Medicine, Columbia University
- **Dallas:** UT Southwestern Medical Center
- **Toronto:** Princess Margaret

**IN 12 COUNTRIES**

SPAIN  
 UK  
 FRANCE  
 IRELAND  
 CANADA  
 GERMANY

DENMARK  
 SWITZERLAND  
 NETHERLANDS  
 ISRAEL  
 US  
 AUSTRALIA

Over the last **12 years** we have invested **over €40 million to date** in research worldwide supporting scientists to develop pioneering new treatments for people living with cancer.

## CRIS MULTIPLYING EFFECT ON CANCER RESEARCH INVESTMENT

On top of the €40 million directly invested, CRIS's research initiatives, chosen by our scientific committee, manage to attract funds from third-party sources to multiply its investment in cancer research.

**X2**

CRIS ENCOURAGES CO-FUNDING WITH OTHER CHARITIES THAT MATCH INITIAL INVESTMENT

**X3**

CRIS INVESTS IN CRIS CANCER RESEARCH UNITS; ATTRACTING INVESTMENT FROM OTHER ENTITIES.

**X10**

CRIS FUNDS PROJECTS ACHIEVING SUCCESSFUL OUTCOMES WHICH ATTRACTS LARGE GRANTS FROM OTHER FUNDING ENTITIES (E.G. THE EU)

## OUR IMPACT ON RESEARCH

**€40M**  
INVESTED

**65**

RESEARCH CENTRES  
AROUND THE WORLD

**247**  
RESEARCHERS AND  
SCIENTISTS



20%

**53**  
TEAMS OF  
RESEARCHERS



55%

**120**  
LINES OF  
RESEARCH



48%

**53**  
NEW TREATMENTS  
DEVELOPED BY  
CRIS TEAMS



29%

**468**  
CLINICAL TRIALS  
IN UNITS AND CRIS  
PROJECTS



69%

**5,954**  
PATIENTS  
BENEFICIARIES OF  
CRIS CLINICAL  
TRIALS

69%

**877**  
SCIENTIFIC  
PUBLICATIONS ON  
DEVELOPMENTS



**848**  
PAPERS AT  
CONFERENCES



**83**  
DOCTORAL  
THESES LINKED  
TO CRIS



**15**  
LICENSED  
PATENTS



**6**  
NEW PATENTS  
ONGOING

**11M**  
POTENTIAL  
BENEFICIARIES OF  
CRIS DEVELOPMENTS  
PER YEAR



# HOW DO WE ACHIEVE THE END OF CANCER?



# FUNDING RESEARCH FOR ADULT AND CHILDHOOD CANCERS

## Fund research into adult cancer

Head and Neck Cancer, Colon Cancer, Breast Cancer, Ovary Cancer, Pancreatic Cancer, Prostate Cancer, Lung Cancer, Kidney Cancer, Melanoma, Multiple Myeloma, Leukaemia, Lymphoma, Cervix Cancer, Thoracic Cancer, Bladder Cancer, Myeloproliferative Neoplasm.



## Fund research into childhood cancer

General, Neuroblastoma, Sarcoma, Leukaemia, Brain Tumours, Lymphoma, Renal.



## Stablish multidisciplinary units in hospitals

Innovative facilities or "units" in hospitals and research centres with multidisciplinary experts all coming together to treat the most difficult cases of cancer.



## Fellowships, scholarships and grants to support researchers

We support researchers at every stage of their careers to give them stability and allow them to excel in their fields.



CRIS carries out research projects not only in CRIS Units but also in other research institutes in Spain, UK and France.

CRIS is also active in other European countries, the US and Canada. Many of these international projects are co-financed by prestigious international institutes such as the Gustave Roussy Institute in France, The Damon Runyon Cancer Research in the US and the Princess Margaret Hospital in Canada.

# 312

## ADULT PROJECTS

TYPE OF CANCER	PROJECTS
Head and Neck Cancer	3
Colon Cancer	3
Breast Cancer	6
Ovary Cancer	4
Pancreatic Cancer	2
Prostate Cancer	9
Lung Cancer	7
Kidney Cancer	2
Melanoma	4
Multiple Myeloma	83
Leukaemia	74
Lymphoma	74
Cervix Cancer	2
Thoracic Cancer	2
Bladder Cancer	1
Myeloproliferative Neoplasm	36

As well as projects focused on specific types of tumours, CRIS also funds general research which can be applied to various cancers such as investigation into cell therapies which specifically target cancer cells. Examples of this type of research are those being carried out at the CRIS Unit for New Experimental Therapies as well as other cutting-edge research into immunotherapy.

# 41

## PAEDIATRIC PROJECTS

TYPE OF CANCER	PROJECTS
General	1
Neuroblastoma	5
Sarcoma	7
Brain Tumours	8
Leukaemia	11
Lymphoma	7
Renal	2

# ESTABLISHING MULTIDISCIPLINARY UNITS IN HOSPITALS



CRIS Cancer UNITS are multidisciplinary teams composed of researchers, bioinformatics specialists, nurses, clinical trial technicians and doctors that combine clinical and laboratory research with patients' treatments in the same institution. By unifying team members with broad expertise, research results can be translated into promising treatments much faster.

In each of the CRIS Units there are several research projects and clinical trials enabling the development of promising treatments and drugs.



## CRIS HAEMATOLOGICAL TUMOURS UNIT

- Specialises in all blood cancer with special focused on leukaemia, lymphoma and myeloma cancers.



## CRIS IMMUNO-ONCOLOGY UNIT

- Immunotherapy is a gateway to hope for many advanced cancers lacking few effective therapies. These include advanced lung cancer, leukaemia, melanoma, bladder cancer and breast cancer



## CRIS UNIT FOR NEW EXPERIMENTAL THERAPIES

- Specialises in solid tumours: lung cancer, lymphomas, leukaemias and multiple myeloma.



## CRIS UNIT FOR ADVANCED THERAPIES IN CHILDHOOD CANCER


- International reference in bone marrow transplantation cell therapies and immunotherapy (CAR-T).
- Blood tumours: acute lymphoblastic leukaemia, acute myeloblastic leukaemia, mixed phenotype leukaemia, aplasia, primary immunodeficiencies leukaemia (Hodgkin's leukaemia).
- Solid tumours: Osteosarcoma, Ewing's sarcoma, medulloblastoma, neuroblastoma and gliomas.

# SUPPORTING RESEARCHERS

CRIS is intrinsically involved in the training of gifted researchers. Through partnerships with various scientific and medical institutions, we carry out many initiatives to support the careers of young researchers. These include scholarships for internships in prestigious international institutions, return grants and masters degrees in research.

- Collaborations
- CRIS Programmes
- 👤 Doctors
- 👥 Researchers

RESEARCHER'S CAREER






**Research holds the key to treating cancer and increasing survival rates. The dedication and hard work of scientific researchers means that more adults and children are surviving cancer and living a better quality of life.**



# CRIS IN FIGURES

*We use funds efficiently, so that every euro invested in cancer has the maximum impact.*

## INVESTMENT IN RESEARCH



**€40M**  
TOTAL 2011-2022

**€8.4M**  
2022

**22%**  
2022 VS 2021

## FUNDS RAISED


We are immensely grateful for the support we have received over the years from our individual and regular donors, their families, corporate partners, community fundraisers and our diligent volunteers, without whom we would not be able to continue funding pioneering research.



- 59%** Regular Donors
- 19%** Major Donors / Legacies
- 10%** Corporates
- 7%** Community Fundraising
- 6%** Others

## 5 YEARS COMMITMENT

CRIS makes long-term commitments with hospitals and research centres to give stability to scientists so they can develop their work. In the next 5 years, CRIS will provide funding of at least 63 million euros.



- 53%** Units
- 20%** Projects
- 10%** Fellowships & International Collaborations
- 9%** Clinical Trials
- 9%** Others



# HIGHLIGHTS 2022



## LEADING CLINICAL TRIAL IN AGGRESSIVE PAEDIATRIC BRAIN TUMOURS

Great Ormond Street Hospital, London(GOSH Charity)

CRIS is funding clinical trials in which 12 children with diffuse midline glioma (DMG), an aggressive type of brain tumour, undergo treatment using new CAR-T therapy. This harnesses the patient's own immune system to attack the cancer cells. At CRIS we are committed to helping scientists give these children new hope. To this end, we also continue to support Prof. C Jones at ICR (London) , Dr Jacques Grill at the Gustave Roussy Institute (Paris) and Dr. Lassaletta at Niño Jesús Hospital (Madrid) in the fight against this aggressive tumour.



## OXFORD - CRIS PROGRAMME

for medical research

Along with our previous commitment to Oxford Cancer, we will be donating a further 400K over 3 years. This is to support a fellow to join the Oxford Cancer Clinical Academic Training Programme. This agreement will be renewed every 3 years.



## OPENING OF AN ADVANCED THERAPY UNIT FOR SOLID TUMOURS

San Carlos Hospital, Madrid, Spain

We have set up and expanded an Experimental Therapy Unit in the San Carlos Hospital in Madrid, Spain. This pioneering unit treats patients with solid tumours and allows them access to the very latest treatments and clinical studies. This is one of four CRIS Units in public hospitals.

**1** NEW  
**Clinical trial**  
**4** Projects in total

**3** years  
Investigation and training  
**400k**

**1** NEW  
**Unit**  
**4** CRIS Units total



## INSTITUTE OF CANCER RESEARCH

ICR

As well as the launch of new projects, CRIS cancer has renewed funding for the following cancer research projects at the Institute of Cancer research: Thoracic Immunotherapy research Group, Centre of Translational Immunotherapy, Head and Neck project , Paediatric Brain Tumour project, Multiple Myeloma project and Chordoma project.



## FIGHT KIDS CANCER

Paediatric trials throughout Europe

CRIS has joined FKC, a Pan-European consortium of foundations, fighting against paediatric cancer. Together, we are delighted to have supported a total of seven projects in 2022 which have had a huge impact on understanding blood and neuroblastoma cancers. The combined resources of this consortium accelerates the implementation of new therapies for children living with these cancers.



## REAL LIFE ONCOLOGY TRIALS IN THE GUSTAVE ROUSSY INSTITUTE

Breast, kidney and lung cancer

These trials aim to establish new protocols to improve the quality of life of patients through more personalised and less toxic treatments. In 2022 we financed 3 trials coordinated by investigators in Spain and France. The Gustave Roussy Oncological Institute in Paris is one of the most prestigious centres of investigation in the world.

**6**  
**Projects**  
**2.6M**  
in total

**7** NEW  
**High impact projects**  
for child blood cancers and neuroblastoma tumours

**3**  
**Clinical trials**  
Breast, lung and kidney  
**1.5M**



# HIGHLIGHTS 2022

## INCREASED INVESTMENT IN PAEDIATRIC CELL THERAPY



CRIS Children's Unit for Advanced Therapies, Hospital de la Paz, Madrid, Spain

This unit allows CRIS researchers to develop therapies for children who do not respond to conventional therapies. In 2022 two new cellular therapies were approved, both of which had been developed in this unit: CAR-T dual for children with relapsing leukaemia and activated NK cells used for clinical trials for childhood sarcomas.

**2** NEW  
**Paediatric cell therapies**  
approved

## NEW CRIS RESEARCH PROGRAMMES



4th edition of The CRIS Research Programme

The programme identifies talent and finances scientists over 5 years, helping them to reach their full potential. Through the programme we have been able to create a community of truly remarkable CRIS researchers.

**6** NEW  
**CRIS Programmes**  
**15.5M**  
since 2019

## US PROSTATE CANCER FOUNDATION



Co-financing of placements in leading international entities

Together with the most prestigious prostate cancer research foundation in the world, CRIS has co-financed 2 researchers through the Young Investigator Awards. This makes 4 researchers in total financed through this collaboration. As well as this, through our investigation into solutions to combat resistance to conventional treatments, there are now 7 investigative projects financed by CRIS for prostate tumours.

**2** NEW  
**Young Investigator Awards**  
**560k**  
**4 AWARDS**  
in total

## CRIS OUT-BACK PROGRAMME



To increase the potential and reap the rewards of investigative talent

This programme consists of 3 years abroad with the guarantee of a year's continuity on the return of the researcher to their home country. The programme also includes training for the awardee and includes the participation of medical companies and prestigious national/international scientists.

**2**  
**Programmes**  
**3 Years**  
abroad  
**+1** In home country

## RENEWING INVESTMENT IN BREAST CANCER RESEARCH



CRIS Research project

We have begun a new project via CRIS Research Projects centred on metastasised breast cancer. With this project we now finance a total of 5 breast cancer projects which study this tumour in all of its phases.

**1** NEW  
**Breast cancer project**  
**6** in total


## MASTERS IN COLLABORATION WITH THE SPANISH SOCIETY OF ONCOLOGICAL RADIOTHERAPY (SEOR)



Oncological Radiotherapy

In collaboration with the SEOR, we have launched a Masters programme in which radiation oncologists receive exclusive training in research and are encouraged to develop their own projects. In this way we can give a helping hand to the careers of the leading investigators of the future.

**1**  
**Master programme**  
**SEOR**  
for radiation oncologists



*By working together, we can accelerate scientific advances in cancer research.*



**We will not stop until every single patient is cured.**



[www.criscancer.org.uk](http://www.criscancer.org.uk)  
[www.criscancer.org](http://www.criscancer.org)